Recruiting PHASE2 INTERVENTIONAL 4-arm NCT06463665

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Sponsor: Genelux Corporation

Conditions Advanced Non-squamous Non-small-cell Lung Cancer Advanced Squamous Non-Small Cell Lung Carcinoma Metastatic Non-squamous Non Small Cell Lung Cancer Metastatic Squamous Non-Small Cell Lung Carcinoma Non-small Cell Lung Cancer Non-small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Stage III Non-small Cell Lung Cancer Stage IV

Interventions Docetaxel Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC Olvimulogene nanivacirepvec Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab Platinum chemotherapy: carboplatin or cisplatin

Updated 12 times since 2024 Last updated: Sep 24, 2025 Started: Sep 26, 2024 Primary completion: Feb 28, 2027 Completion: Jul 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Non-squamous Non-small-cell Lung Cancer and Advanced Squamous Non-Small Cell Lung Carcinoma and is currently actively recruiting participants. Genelux Corporation leads this study, which shows 12 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2

▶ Show 7 earlier versions

Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Feb 2025 — May 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Oct 2024 — Dec 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genelux Corporation
Newsoara Biopharma Co., Ltd.

Data source: Genelux Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Baltimore, United States , Baytown, United States , Bullhead City, United States , Canton, United States , Clermont, United States , Coral Springs, United States , Dearborn, United States , Farmington Hills, United States , Fort Lauderdale, United States and 5 more locations